In a turbulent market environment, VINC stock has reached its 52-week low, trading at $1.62, with technical indicators from InvestingPro showing the stock in oversold territory. This price level ...
SAN MATEO, Calif. - Vincerx Pharma, Inc. (NASDAQ:VINC), a clinical-stage biopharmaceutical company with a current market capitalization of $2.77 million, and Oqory, Inc. announced promising results ...
Companies also provide insights into proposed strategic mergerSAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx ...
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...
Shares of Logility Supply Chain Solutions, Inc. LGTY rose sharply in today's pre-market trading after Aptean announced an ...
Knuckles: The Chris Nilan Story; One-man show with former Habs enforcer to hit the stage in late May
I have been a fan of Chris Nilan since he made his debut with the Montreal Canadiens during the 1979-80 season. Back then my ...
Daniel Hemetsberger narrowly missed out on the downhill podium in fourth place at the Hahnenkamm race in Kitzbühel. However, ...
The company has already cut its workforce, seen a leadership change and agreed to be acquired. Here's what's next.
EST Vincerx Pharma (VINC) files $100M mixed securities shelfInvest with Confidence: Follow TipRanks' Top Wall Street Analysts to uncover ...
Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback